Erectile dysfunction is the inability to develop and maintain an erection for satisfactory sexual intercourse or activity in the absence of an ejaculatory disorder such as premature ejaculation. Causes include medications, chronic illnesses, poor blood flow to the penis, drinking too much alcohol, or being too tired.
Shares of Apricus Biosciences, Inc. (Nasdaq:APRI) climbed more than 20% in pre-market trading Wednesday after the company said that Mexico has granted its commercialization partner, Ferring Pharmaceuticals, market approval for Vitaros(R), an on-demand topical cream indicated for the treatment of patients with erectile dysfunction.
According to the biopharmaceutical company, Mexico is the twenty-sixth country in which its commercial product has been approved, including Argentina, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Lebanon, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland and the United Kingdom.
Apricus Biosciences is advancing innovative medicines in urology and rheumatology.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer